- Home
- KOSS vs LPTX Comparison
KOSS vs LPTX Comparison
Compare KOSS & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOSS
- LPTX
- Stock Information
- Founded
- KOSS 1953
- LPTX 2011
- Country
- KOSS United States
- LPTX United States
- Employees
- KOSS N/A
- LPTX N/A
- Industry
- KOSS Consumer Electronics/Appliances
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KOSS Consumer Staples
- LPTX Health Care
- Exchange
- KOSS Nasdaq
- LPTX Nasdaq
- Market Cap
- KOSS 43.6M
- LPTX 35.4M
- IPO Year
- KOSS N/A
- LPTX N/A
- Fundamental
- Price
- KOSS $4.50
- LPTX $0.47
- Analyst Decision
- KOSS
- LPTX Hold
- Analyst Count
- KOSS 0
- LPTX 1
- Target Price
- KOSS N/A
- LPTX N/A
- AVG Volume (30 Days)
- KOSS 55.8K
- LPTX 1.4M
- Earning Date
- KOSS 10-30-2025
- LPTX 11-13-2025
- Dividend Yield
- KOSS N/A
- LPTX N/A
- EPS Growth
- KOSS N/A
- LPTX N/A
- EPS
- KOSS N/A
- LPTX N/A
- Revenue
- KOSS $13,493,080.00
- LPTX N/A
- Revenue This Year
- KOSS N/A
- LPTX N/A
- Revenue Next Year
- KOSS N/A
- LPTX N/A
- P/E Ratio
- KOSS N/A
- LPTX N/A
- Revenue Growth
- KOSS 11.58
- LPTX N/A
- 52 Week Low
- KOSS $4.00
- LPTX $0.22
- 52 Week High
- KOSS $8.59
- LPTX $3.82
- Technical
- Relative Strength Index (RSI)
- KOSS 36.43
- LPTX 49.57
- Support Level
- KOSS $4.59
- LPTX $0.39
- Resistance Level
- KOSS $4.78
- LPTX $0.56
- Average True Range (ATR)
- KOSS 0.26
- LPTX 0.05
- MACD
- KOSS -0.03
- LPTX -0.01
- Stochastic Oscillator
- KOSS 14.75
- LPTX 45.81
About KOSS Koss Corporation
Koss Corp is engaged in the design, manufacture, and sale of stereo headphones and related accessory products. It operates in the audio/video industry segment of the home entertainment industry. The company markets a line of headphones, wireless Bluetooth headphones, wireless Bluetooth speakers, computer headsets, telecommunications headsets, and active noise-canceling headphones. The majority of the firm's revenue is derived from sales of stereo headphones. The Company also sells products to distributors for resale to school systems, and directly to other manufacturers for inclusion with their own products.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.